Combination therapy for small cell lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs — sintilimab (an immunotherapy) and anlotinib (a targeted therapy) — for people with small cell lung cancer that has worsened after previous immunotherapy. The goal is to see if this combination can help control the cancer when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have small cell lung cancer that has spread or come back after at least 3 months of standard immunotherapy treatment.
- You must have at least one tumor that can be measured on a scan.
- You should be generally active and able to care for yourself (ECOG score 0 or 1).
- Your major organs (heart, liver, kidneys, blood cells) must be working reasonably well, as confirmed by blood tests.
- You must not have certain serious heart, lung, or bleeding conditions, or an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests whether giving a combination of two drugs (sintilimab and anlotinib) before surgery can help shrink non-small cell lung cancer tumors and improve outcomes. It is for people with stage IB to IIIB cancer that can be removed with surgery and who have not had treatment yet.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Resistance to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.